A Clinical Investigation to Evaluate the Safety and Efficacy of IBS in Patients With Coronary Artery Disease
A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 518 participants.
Also called NCT05206084
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 518 participants
- Registry
-
NCT05206084
-
- Other papers using this trial's data
- Sirolimus-Eluting Iron Bioresorbable Scaffolds vs Everolimus-Eluting Stents for Percutaneous Coronary Intervention: A Randomized Trial (IRONMAN II)
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT05206084. Randomized; single masking; primary purpose treatment. Start 2022-03-10 (actual); primary completion 2024-12-29 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Clinical Investigation to Evaluate the Safety and Efficacy of IBS in Patients With Coronary Artery Disease
- Acronym
- IRONMAN-II
- Condition
- Coronary Artery Disease
- Intervention (Device)
- Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System (IBS)
- Intervention (Device)
- Abbott Vascular XIENCE Everolimus Eluting Coronary Stent System
- Lead sponsor
- Biotyx Medical (Shenzhen) Co., Ltd.
Record details
- Record id
cardio:ct-nct05206084- Content hash
152b5db96c5d3aacb4da0cd86183bcb01fac0cf7e4bac01719c6b517bf43ed8b